science wire

« BACK

Pharmacology



Results 1301 - 1331 of 1331.
« Previous 1 ... 23 24 25 26 ... 27


Health - Pharmacology - 26.01.2010
Die Ergotherapie von morgen findet am Computer statt
Zurich - University of Zurich Nach Hirnverletzungen müssen Patienten Bewegungen neu einüben. Neuerdings helfen ihnen dabei Computergames.

Pharmacology - Health - 20.01.2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine
Results of the TRANSFORMS[1] and FREEDOMS[2] studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine , providing c

Health - Pharmacology - 20.01.2010
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer
Basel - Novartis Basel, January 20, 2010 - Patients in Japan will benefit from the approval of three new Novartis medicines - EquaĀ® (vildagliptin), marketed as GalvusĀ® in the European Union , for t

Pharmacology - Business / Economics - 18.01.2010
Novartis providing equivalent of over USD 2.5 million in immediate emergency aid for victims of Haiti earthquake
Basel - Novartis Through its local organizations in countries throughout the region, Novartis is providing the equivalent of over USD 2.5 million in immediate emergency aid for victims of the recent earthquake in Haiti.

Pharmacology - Physics - 18.01.2010
Attacking the lifeline of tumour cells
Attacking the lifeline of tumour cells
A Finnish-Swiss team cracks the atomic structure of a major cancer drug target Researchers at Biomedicum Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand-binding domain of a vascular endothelial growth factor (VEGF) receptor in complex with one of its ligands (VEGF-C).

Health - Pharmacology - 13.01.2010
Mikro-Teile gegen Anämie
Zurich - University of Zurich Für Hämoglobin-Erbkrankheiten gibt es gute Therapien. Weiterhin ist aber ein Teil der Patienten auf regelmässige Transfusionen angewiesen.

Pharmacology - Health - 11.01.2010
Novartis launches schizophrenia treatment Fanapt in the US, offering patients an attractive alternative to existing medications
"Schizophrenia remains one of the most debilitating and difficult to treat mental illnesses.

Pharmacology - Health - 23.12.2009
Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure
Basel - Novartis - Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera Inc.

Health - Pharmacology - 21.12.2009
All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world
Basel - Novartis WHO prequalification facilitates purchasing through UN agencies and thus enhances access for developing world countries to Novartis A(H1N1) 2009 vaccines that meet unified standards of quality and safety.

Health - Pharmacology - 18.12.2009
Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults
Basel - Novartis (Meningococcal Group A, C, W-135 and Y-CRM Conjugate Vaccine) has received a Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

Pharmacology - Health - 09.12.2009
Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases
09.12.2009 / Basel - Novartis Basel, December 9, 2009 - Novartis is set to sustain its leading global position in oncology by expanding the range of indications for several marketed the

Pharmacology - Health - 08.12.2009
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
08.12.2009 / Basel - Novartis At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400 mg once dai

Pharmacology - Health - 03.12.2009
Novartis receives approval in the European Union for Onbrez® Breezhaler®, a new once-daily bronchodilator for patients with COPD
03.12.2009 / Basel - Novartis Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg

Health - Pharmacology - 02.12.2009
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
02.12.2009 / Basel - Novartis Basel, December 2, 2009 - Novartis announced today that new data, including a late-breaking presentation on Tasigna"(nilotinib) in a form of chronic myeloi

Pharmacology - Health - 25.11.2009
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
25.11.2009 / Basel - Novartis Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for myelofibrosis, a life-threatening blood disorder

Health - Pharmacology - 24.11.2009
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
24.11.2009 / Basel - Novartis Facility designed to supply 150 million doses of pandemic vaccine within 6 months of influenza pandemic declaration; facility ready to respond to a pandemi

Health - Pharmacology - 17.11.2009
Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
17.11.2009 / Basel - Novartis Interim clinical data from approximately 4,000 individuals suggest that half a dose of the currently US-approved Novartis unadjuvanted Influenza A(H1N1) 20

Health - Pharmacology - 13.11.2009
Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
13.11.2009 / Basel - Novartis Approvals in Germany and Switzerland demonstrate expanded adoption of new cell culture technology - an important milestone in replacing 50 year-old egg-bas

Pharmacology - Health - 12.11.2009
Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment
12.11.2009 / Basel - Novartis PrevacidĀ®24HR provides America 's 50 million frequent heartburn sufferers[1] with convenient and easy accessibility to this effective heartburn treatment

Health - Pharmacology - 05.11.2009
Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
05.11.2009 / Basel - Novartis Clinical trials in more than 1,850 individuals across all age groups show strong efficacy, that can induce immune responses associated with protection agai

Business / Economics - Pharmacology - 04.11.2009
Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
04.11.2009 / Basel - Novartis Basel, November 4, 2009 - Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co.

Pharmacology - Business / Economics - 03.11.2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
03.11.2009 / Basel - Novartis Additional USD 250 million invested in advanced technical R&D and manufacturing facility opening in Changshu, furthering economic development of Jiangs

Health - Pharmacology - 29.10.2009
Novartis on track to deliver Influenza A (H1N1) vaccine for the US
29.10.2009 / Basel - Novartis To date, Novartis has shipped more than 7.5 million doses of Influenza A (H1N1) vaccines in multi-dose vials and pre-filled syringes ready to use, a

Health - Pharmacology - 28.10.2009
Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease
28.10.2009 / Basel - Novartis Ilaris is a monoclonal antibody that selectively targets and blocks interleukin-1 beta (IL-1Ɵ), the trigger for inflammation and tissue damage in CAPS pat

Pharmacology - Health - 23.10.2009
Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure
23.10.2009 / Basel - Novartis Basel , October 23, 2009 - The European Commission has granted Novartis marketing authorization for Exforge HCT" a new 3-in-1 treatment for people with high blood pressure.

Health - Pharmacology - 22.10.2009
Novartis delivers strong new product momentum and operational performance in first nine months of 2009
22.10.2009 / Basel - Novartis Net income of USD 6.1 billion down 8% due to negative currency impact, Alcon-related financing costs and USD 189 million of associated companies cha

Health - Pharmacology - 20.10.2009
New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
20.10.2009 / Basel - Novartis Basel, October 20, 2009 - New Phase II results show that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectab

Pharmacology - Health - 20.10.2009
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients
20.10.2009 / Basel - Novartis Basel, October 20, 2009 - Novartis announced today that TasignaĀ® (nilotinib) met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug GlivecĀ® (imatinib).

Pharmacology - Health - 19.10.2009
Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD
19.10.2009 / Basel - Novartis Basel, October 19, 2009 - Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) as part of the US regulatory revi

Health - Pharmacology - 19.10.2009
Leading Dengue and TB scientists discuss new clinical research approaches and models of excellence for clinical research and trials in endemic regions
19.10.2009 / Basel - Novartis NEHCRI is a unique role model for clinical TB and Dengue research in endemic regions, utilizing local input to build capacity and develop health infrastruc

Pharmacology - Health - 12.10.2009
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia
12.10.2009 / Basel - Novartis Basel, October 12, 2009 - Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral med
« Previous 1 ... 23 24 25 26 ... 27

This site uses cookies and analysis tools to improve the usability of the site. More information. |